SmithKline's remaining upstream merger options limited after termination of Glaxo talks.
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE REMAINING CHOICES FOR UPSTREAM MERGER LIMITED now that negotiations with Glaxo Wellcome have fallen through. Among the top four pharmaceutical firms worldwide -- Glaxo, Merck, Novartis and Bristol-Myers Squibb -- three probably can be ruled out as merger candidates for SB. An outright acquisition of a smaller firm, such as perennial acquisition candidates Warner-Lambert or Schering-Plough, could be an alternative for SmithKline Beecham, but such a move would not bring the company into the top rankings of the pharmaceutical industry as envisioned by CEO Jan Leschly.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning